Picture of Sartorius Stedim Biotech SA logo

DIM — Sartorius Stedim Biotech SA News Story

0.000.00%
fr flag iconLast trade - 00:00
HealthcareSpeculativeLarge CapHigh Flyer

Brief: Sartorius Stedim Biotech Eyes 60-85 Bps Underlying EBITDA Margin Increase Per Year From 2027

March 17 (Reuters) - Sartorius Stedim Biotech SA STDM.PA:

SARTORIUS STEDIM BIOTECH SHARPENS STRATEGY WITH BIOPHARMA FOCUS AND SETS NEW MID-TERM GROWTH TARGETS

TARGETS ORGANIC SALES REVENUE GROWTH OF 9-12% PER YEAR IN CONSTANT CURRENCIES FROM 2027

UNDERLYING EBITDA MARGIN EXPECTED TO INCREASE BY 60-85 BASIS POINTS PER YEAR FROM 2027

Source text: ID:nEQ80jnTRa

Further company coverage: STDM.PA

 (Gdansk Newsroom)

 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))

Recent news on Sartorius Stedim Biotech SA

See all news